Latest Intelligence on Therapy Area in Belgium

Published within

« | 1 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Virco: looking into the future of AIDS therapy

Published By Datamonitor
17 Jul 2001
CommentWire
CommentWire

UCB: positive outlook for Keppra

UCB has reported significant top-line phase III results for its epilepsy medicine Keppra over placebo in reducing the frequency of partial onset seizures in pediatric patients. While these results demonstrate Keppra's broad potential to reduce the burden of epilepsy across a wider-range of patients, they also point to a positive future for UCB's epilepsy franchise.

Published By Datamonitor
20 Apr 2007
CommentWire
CommentWire

UCB: development of Keppra's successor makes headway

UCB has initiated a Phase III clinical program for brivaracetam as an adjunctive treatment in partial-onset epilepsy. Should it perform well here and gain marketing approval, the launch of this drug would serve to strengthen UCB's epilepsy franchise, as well as potentially representing an important treatment option for patients with refractory epilepsy.

Published By Datamonitor
26 Oct 2007
CommentWire
CommentWire

UCB: continuing the European Mid-Pharma consolidation craze

Having enjoyed past success from acquisitions, Belgian-based UCB is now looking to Schwarz Pharma, with its impressive late-stage pipeline, to boost its growth potential. This merger agreement is the latest in a recent 'acquisition frenzy', and highlights the current trend towards consolidation in the European pharmaceutical sector.

Published By Datamonitor
26 Sep 2006
CommentWire
CommentWire

UCB/Schwarz: a leading CNS proposition moves a step closer

The $5.5 billion takeover of Schwarz Pharma by Belgian rival UCB looks likely to go ahead, as preliminary figures show that UCB has received tenders in excess of 76% of the share capital of Schwarz Pharma. In addition to generating significant synergies, the deal is expected to create a leading neurology-focused pharmaceuticals group.

Published By Datamonitor
12 Dec 2006
CommentWire
CommentWire

Solvay/Biovail: too little, too late for Teveten

Although Solvay/Biovail's Teveten (eprosartan) has demonstrated benefits in isolated systolic hypertension, Solvay has been reluctant to file for this indication. The results of the most recent trial may well be too little too late now that Teveten's major competitors, such as Diovan (valsartan), are also targeting this indication.

Published By Datamonitor
21 May 2003
CommentWire
CommentWire

Solvay, Wyeth and Lundbeck: high expectations for schizophrenia drug

Results of safety and efficacy studies presented by Solvay, Lundbeck and Wyeth demonstrate that bifeprunox improved stability in schizophrenia patients versus placebo. The favorable weight and metabolic profile of bifeprunox is likely to boost patient compliance and will be a key differentiating factor for this drug when it enters the market.

Published By Datamonitor
07 Dec 2006
CommentWire
CommentWire

Schering-Plough/Centocor: wider Remicade indication

Published By Datamonitor
06 Feb 2001
CommentWire
CommentWire

ImmunoMedics/UCB: looking to lupus

ImmunoMedics' shares have risen by around 14% after the company announced a profitable licensing deal with UCB for epratuzumab, a B-cell targeted therapy with promise in autoimmune disorders, specifically lupus. The deal should also prove a good move for UCB, which is gaining the rights to a promising drug candidate with blockbuster potential.

Published By Datamonitor
11 May 2006
Expert View
Expert View

Ablynx: new data announced in rheumatoid arthritis for potential biobetter ozoralizumab

Ablynx is looking for a new partner to progress the development of anti-tumor necrosis factor (TNF) pipeline drug ozoralizumab, which utilizes novel "nanobody" technology to achieve some differentiating factors in this profitable but crowded market. The new results are promising, but true differentiation among anti-TNF brands is hard to achieve.

Published By Datamonitor
27 Jun 2012

« | 1 | » »|

No help is available.